Literature DB >> 33280497

MAP17 contributes to non-small cell lung cancer progression via suppressing miR-27a-3p expression and p38 signaling pathway.

Qian Liang1, Huan Zhang1.   

Abstract

PROBLEM AND AIM: The overexpression of MAP17 has been reported in various human carcinomas. However, its molecular mechanism in non-small cell lung cancer (NSCLC) has not been fully understood. Our study aimed to reveal the molecular mechanism of NSCLC that involved MAP17 and identify its target miRNA.
METHODS: RT-qPCR and immunoblot assays were conducted to measure the expression of mRNA and protein in NSCLC tissues and cell lines. Meanwhile, the A549 cells (an NSCLC cell line) were randomly assigned to the MAP17 overexpression group, the MAP17 knockdown group and negative control group to study the roles of MAP17 in cell viability, cell proliferation, migration, invasion, and apoptosis by performing Trypan blue exclusion, MTT, colony formation, transwell, wound healing and flow-cytometric apoptosis assays. The luciferase reporter assay was conducted to confirm the target relationship between MAP17 and miR-27a-3p.
RESULTS: The upregulation of MAP17 mRNA and protein was observed in NSCLC tissues and cell lines. In vitro, the positive roles of MAP17 on cell viability, migration, and invasion were confirmed in A549 cells. It was also found that MAP17 could inhibit cell apoptosis by suppressing the activation of the p38 pathway. This research eventually proved the target relationship between MAP17 and miR-27a-3p, and that miR-27a-3p reversed the effects of MAP17 in A549 cells by directly targeting MAP17.
CONCLUSIONS: MAP17 plays an oncogenic role in NSCLC by suppressing the activation of the p38 pathway. Apart from that, the miR-27a-3p can inhibit the expression of MAP17 to suppress the NSCLC progression.

Entities:  

Keywords:  MAP17; Non-small cell lung cancer (NSCLC); miR-27a-3p; p38 pathway

Mesh:

Substances:

Year:  2020        PMID: 33280497      PMCID: PMC7834051          DOI: 10.1080/15384047.2020.1836948

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  49 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Genistein inhibits A549 human lung cancer cell proliferation via miR-27a and MET signaling.

Authors:  Yang Yang; Aimin Zang; Youchao Jia; Yanhong Shang; Zhuoqi Zhang; Kun Ge; Jinchao Zhang; Wufang Fan; Bei Wang
Journal:  Oncol Lett       Date:  2016-07-06       Impact factor: 2.967

3.  MiR-96-5p promotes the proliferation, invasion and metastasis of papillary thyroid carcinoma through down-regulating CCDC67.

Authors:  Z-M Liu; Z-Y Wu; W-H Li; L-Q Wang; J-N Wan; Y Zhong
Journal:  Eur Rev Med Pharmacol Sci       Date:  2019-04       Impact factor: 3.507

4.  p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion.

Authors:  Bangxing Hong; Haiyan Li; Mingjun Zhang; Jingda Xu; Yong Lu; Yuhuan Zheng; Jianfei Qian; Jeffrey T Chang; Jing Yang; Qing Yi
Journal:  Int J Cancer       Date:  2014-05-16       Impact factor: 7.396

Review 5.  MicroRNAs in tumorigenesis.

Authors:  Kai Ove Skaftnesmo; Lars Prestegarden; David R Micklem; James B Lorens
Journal:  Curr Pharm Biotechnol       Date:  2007-12       Impact factor: 2.837

6.  EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties.

Authors:  Yi Shao; Hui Lv; Dian-Sheng Zhong; Qing-Hua Zhou
Journal:  Oncol Lett       Date:  2018-02-27       Impact factor: 2.967

7.  Identification of a novel gene, selectively up-regulated in human carcinomas, using the differential display technique.

Authors:  O Kocher; P Cheresh; L F Brown; S W Lee
Journal:  Clin Cancer Res       Date:  1995-10       Impact factor: 12.531

8.  MAP17 overexpression is a common characteristic of carcinomas.

Authors:  Maria V Guijarro; Juan F M Leal; Jesus Fominaya; Carmen Blanco-Aparicio; Soledad Alonso; Matilde Lleonart; Josep Castellvi; Lidia Ruiz; Santiago Ramon Y Cajal; Amancio Carnero
Journal:  Carcinogenesis       Date:  2007-04-09       Impact factor: 4.944

9.  MAP17 enhances the malignant behavior of tumor cells through ROS increase.

Authors:  Maria V Guijarro; Juan F M Leal; Carmen Blanco-Aparicio; Soledad Alonso; Jesús Fominaya; Matilde Lleonart; Josep Castellvi; Santiago Ramon y Cajal; Amancio Carnero
Journal:  Carcinogenesis       Date:  2007-06-04       Impact factor: 4.944

10.  Elevation of MAP17 enhances the malignant behavior of cells via the Akt/mTOR pathway in hepatocellular carcinoma.

Authors:  Xinhuang Chen; Yan Liao; Yaqun Yu; Pengpeng Zhu; Jun Li; Liling Qin; Weijia Liao; Zhaoquan Huang
Journal:  Oncotarget       Date:  2017-10-04
View more
  2 in total

1.  A Novel Tumor Suppressor Gene, ZNF24, Inhibits the Development of NSCLC by Inhibiting the WNT Signaling Pathway to Induce Cell Senescence.

Authors:  Bo Pang; Yong Wang; Xiaoyan Chang
Journal:  Front Oncol       Date:  2021-07-27       Impact factor: 5.738

2.  Lysophosphatidic acid receptor 6 regulated by miR-27a-3p attenuates tumor proliferation in breast cancer.

Authors:  J Lei; S Guo; K Li; J Tian; B Zong; T Ai; Y Peng; Y Zhang; S Liu
Journal:  Clin Transl Oncol       Date:  2021-09-12       Impact factor: 3.405

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.